DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Friday morning. The firm issued a hold rating on the stock.

Several other analysts have also issued reports on the company. HC Wainwright upped their target price on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Trading Down 5.5 %

DBVT opened at $4.47 on Friday. The stock has a market capitalization of $91.95 million, a P/E ratio of -0.99 and a beta of 0.64. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $9.49. The stock has a 50-day moving average price of $3.43 and a 200-day moving average price of $3.84.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.